Ding L, Yang B, Yao X. Re: Fred Saad, Noel W. Clarke, Mototsugu Oya, et al. Olaparib plus Abiraterone Versus Placebo plus Abiraterone in Metastatic Castration-resistant Prostate Cancer (PROpel): Final Prespecified Overall Survival Results of a Randomised, Double-blind, Phas Eur Urol 2023 Nov 23:S0302-2838(23)03226-8. doi: 10.1016/j.eururo.2023.
PMID: 38000965